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CONCLUSIONS: The EQ-5D was easily understood and
accepted by this cohort of patients with ACS and can serve as a
valid measure of health-related quality of life in ACS population-
based studies.
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AUSTRALIAN PATIENTS
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OBJECTIVES: Cough is a widely recognised adverse effect of
Angiotensin-converting enzyme inhibitors (ACEI) and has been
linked to poor medication compliance and potentially poorer
quality of life (QoL). Clinically, AIIRAs (Angiotensin II receptor
antagonists) have been shown to reduce the occurrence of cough
relative to ACEIs. This study was designed to determine the
impact of cough on patients’ QoL by using generic and cough-
speciﬁc QoL measures and contingent valuation (CV) method-
ology. METHODS: Ninety-one patients currently on ACEIs and
48 patients switched from ACEIs to AIIRAs were recruited from
across Australia. Both groups were asked to complete the World
Health Organisation Quality of Life questionnaire (brief version)
(WHOQoL-Bref) and to answer general questions on QoL,
health and demographics. Those on ACEIs also completed the
Cough-speciﬁc Quality of Life Questionnaire (CQLQ). A CV
question, which gave the participants the choice between an
ACEI and AIIRA level of cough, was also asked. The CV health
states were based on clinical trial data. RESULTS: Respondents
ranged in age from 38–81 years (mean = 58.4 years) in the ACEI
group, and 31–82 years (mean = 55.6 years) in the AIIRA group.
A signiﬁcant relationship between cough severity and QoL
existed for the CQLQ (p = 0.003) and the WHOQoL-Bref (p =
0.025) in the ACEI group. Cough severity was signiﬁcantly
related to difﬁculty of sleeping (p = 0.009), being self-conscious
(p = 0.015), and exhaustion (p = 0.002). The CV analysis for the
AIIRA scenario yielded a mean willingness-to-pay of AUS$16.80
per month for those on ACEIs and AUS$16.20 per month for
those on AIIRAs. CONCLUSION: Overall, the results from this
study illustrate the impact that ACEI-induced cough has on
quality of life. Both patient groups were willing to pay over
AUS$16 per month to experience effective hypertension control
associated with a lower risk of experiencing cough. This suggests
that the impact of cough on QoL may be more than previously
considered and should be considered when selecting anti-
hypertensive treatment.
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OBJECTIVE: To assess the acute effects of smoking cessation on
health-related quality of life (HQL). METHODS: Question-
naires were mailed to patients enrolled in a smoking-cessation
program just prior to quit date (T1) and 1-week post-quit (T2).
HQL was assessed by the Smoking Cessation Quality of Life
Questionnaire (SCQoLQ). It contains 5 cessation-targeted scales:
social interactions, self-control, sleep, cognitive-functioning, and
anxiety. The SF-36 is included as a generic core. Other data
included patient demographics, duration of smoking, Fagerstrom
scale, and smoking status at T2. Student’s t-test for paired data
was used to compare the T1–T2 HQL scores. Student’s t-test for
independent samples compared the HQL of a higher addiction
(HA) group (Fagerstrom > 6) to a lower addiction (LA) group
(Fagerstrom < = 6). RESULTS: Respondents (n = 34, 12 in HA-
group, 22 in LA-group) averaged 48.6 (+12.0) years of age and
were primarily Caucasian (97%) and female (72.2%). The mean
Fagerstrom score was 5.0 (+2.3). Overall, one week into cessa-
tion (T1 to T2) there was signiﬁcant worsening in SCQoLQ
anxiety (71.5 + 25.1 to 61.1 + 26.0, p = 0.04) and cognitive-
functioning (72.2 + 20.4 to 61.3 + 23.9, p = 0.02) scores and
improved self-control (46.5 + 22.2 to 5.1 + 18.5, p = 0.001) and
SF-36 general health (65.2 + 18.4 to 70.5+16.9, p = 0.01). At
T1, all LA-group HQL scores were higher than HA-group scores,
signiﬁcantly for sleep, cognitive-functioning, anxiety, and SF-36
role-emotional and mental-health. Between T1 and T2 there was
signiﬁcant decline in sleep, cognitive-function, and anxiety and
improved self-control in the LA-group; the HA-group had sig-
niﬁcant improvement in self-control and SF-36 general-health,
but no signiﬁcant changes in other scores. All SCQoLQ scores
at T2 for LA were higher than either the T1 or T2 SCQoLQ
scores for the HA. CONCLUSIONS: Generally, HQL changes
one-week into a smoking cessation attempt. Smokers with higher
addiction have lower HQL when they begin their cessation
attempt, while smokers with lower addiction have greater change
in their HQL.
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OBJECTIVES: 1) To determine the prevalence of depression
symptoms and to describe antidepressant treatment in a popu-
lation with a history of ACS, and 2) To describe the relationship
of depression treatment adequacy and health-related quality of
life (HRQL) controlling for patient, treatment and disease char-
acteristics. METHODS: All ACS-diagnosed patients discharged
from a university-afﬁliated hospital during a 3-year period were
mailed a survey that included the SF-8, EQ-5D and other self-
reported measures of disease and treatment (e.g. physical func-
tioning, comorbidity, medication compliance, perceived cardiac
severity). Patients were categorized based on self-report of
depressive symptoms and antidepressant medication. Adjusted
mean HRQL measures were determined by least square mean
analysis controlling for independent variables. RESULTS: Of
1217 patients, 490 (40.3%) responded. Respondents averaged
65.2 (± 11.3) years of age; 71% male; 92% Caucasian; 64% with
MI history; 17% had their most recent cardiac event within 6
months. No depressive symptoms and no depression treatment
(without depression) were reported by 59.8%; 27.6% reported
untreated depressive symptoms (untreated); 8.6% reported
depressive symptoms and antidepressant medication (under-
treated); and 4.1% reported no symptoms and antidepressant
medication (adequately treated). Adjusted mean SF-8 Mental
Component Summary (MCS-8) scores were 52.8, 52.5, 42.8, and
40.2 for patients without depression, adequately treated,
untreated, and undertreated respectively (p < 0.0001 for all 
pairwise comparisons except for patients without depression vs.
adequately treated and untreated vs. undertreated). The only
other signiﬁcant pairwise HRQL comparison was between the
adjusted mean general health VAS scores for nondepressed and
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undertreated patients; there were no differences in SF-8 Physical
Component Summary scores by group. CONCLUSIONS:
Depressive symptoms are common in patients diagnosed with
ACS and appear to be related to lower mental HRQL. Though
the need for prospective analyses remains, these observations
stress the importance of identiﬁcation of depressive symptoms in
this population and initiation of appropriate psychotherapeutic
treatment.
PCV39
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OBJECTIVES: To assess health status in high-risk subjects
undergoing noncardiac vascular surgery in the United States.
METHODS: Health status data were collected as part of a phar-
macoeconomic (PE) substudy from a clinical trial in noncardiac
vascular surgery patients. The analysis population consisted of
subjects (mean age = 70.0) from the primary clinical analysis
population of U.S. subjects who consented to participate in the
PE substudy. Health status was measured using the 12-item
Short-Form Health Survey (SF-12 acute, version 1) at baseline
and post-operative Day 30. Physical and mental component
summary scores (PCS and MCS) were calculated using published
scoring algorithms. RESULTS: Of the 370 subjects in the U.S.
clinical population, 229 subjects (62%) provided information on
the SF-12. Differences in the distribution of age, gender, race,
and index procedures were similar in both clinical and PE sub-
study samples. Mean scores were 30.6 (SD = 10.7) at baseline
and 32.8 (10.6) at Day 30 for the PCS; corresponding scores
were 50.3 (12.4) and 50.4 (10.5) for the MCS. There was a slight
improvement in the mean change from baseline for the PCS and
no real improvement for the MCS. The proportion of patients
whose SF-12 scores improved from baseline was 54.2% and
45.9% for the PCS and MCS, respectively. Mean baseline SF-12
scores on the PCS for these subjects were noticeably lower than
those from the general U.S. population norms aged 65–74 (PCS
mean = 43.9, SD = 9.3) and from other common chronic dis-
eases. CONCLUSIONS: The data suggest a marginal improve-
ment in PCS, but not MCS scores at post-operative Day 30. A
longer follow-up may have been necessary to detect a noticeable
improvement in health status. High-risk patients undergoing
noncardiac vascular surgery have relatively low levels of 
physical functioning and well-being compared with many other
diseases.
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OBJECTIVE: Assessment of quality of drug treatment can be
expensive and time consuming. Database of sickness fund was
used and a set of non-speciﬁc and disease-speciﬁc indicators
according to treatment guidelines was developed to assess the
quality of drug treatment of coronary artery disease (CAD) in
counties population. METHODS: Patients from 5 selected coun-
ties in Slovak Republic treated for CAD were identiﬁed from
database of General Sickness Fund. Overall prescribed treatment
for CAD in 2001 was assessed according to the quantity and
quality of prescribed drugs using developed set of 10 quality indi-
cators. RESULTS: A total of 52,487 patients (10.3%) were
treated for CAD, 65% were female. The mean age was 68.3
years. Seventy-seven percent were also receiving treatment for
hypertension and 18% had diabetes. Sixty-ﬁve percent were
treated with long-acting nitrates, and in almost 25%, long-acting
nitrates were the only treatment for CAD. Sixty percent were not
receiving beta-blocking agents. Antithrombotic therapy was 
prescribed for two thirds of patients. Only 15% were receiving
hypolipidemic agents. Performance in each county using 10
quality indicators was assessed separately and huge differences
between counties were found. CONCLUSIONS: The overall
score achieved with quality indicators was unsatisfactory. The
results show low compliance of physicians with existing guide-
lines and the need for activities for improving the quality of drug
treatment of CAD.
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OBJECTIVES: The purpose of this study is to compare medica-
tion adherence in patients initiated on a combination therapy of
Calcium Channel Blockers (CCB) and Statins with those on CCB
or Statins mono-therapy. METHODS: Using pharmacy claims
data of a California Medicaid population from 1995 to 2002,
we computed a 90, 180, 270 and 365-day Medication Posses-
sion Ratio (MPR) for the purpose of measuring medication
adherence. Four patient cohorts are compared: 1) CCB only (N
= 33,367); 2) Statins only (N = 27,536); 3) Combination
Therapy: CCB + Statin (initiated on CCB, Statin addition) (N =
14,866); and 4) Combination Therapy: Statin + CCB (initiated
on Statin, CCB addition) (N = 5944). Patients with both a CCB
and a Statin medication ﬁlled on the same day (N = 1265) are
included in both Cohorts 3 and 4. Patients must have Medicaid
coverage for at least six months prior to initial CCB or Statin
medication use to be included in the analysis. Continued eligi-
bility for an adequate length of time is required to compute MPR
for given days (e.g., 3 months continued eligibility to compute a
90-day MPR). RESULTS: The average 180-day MPR was 54.5%
for Cohort 3 and 52.1% for Cohort 4, which is lower than that
of CCB and Statin mono-therapy (56.5% and 59.7%, respec-
tively). However, the average MPR for the combination therapy
increased to 64.4% with the addition of a CCB and to 65.2%
with the addition of a Statin. In general, average MPRs increased
over the years. For the Statins-only cohort, the 180-day MPR
increased from 50.8% in 1995 to 64.2% in 2001. CONCLU-
SIONS: Multiple medications appear to reduce medication
adherence. For patients using combination therapy of CCBs and
Statins, it may be beneﬁcial to develop a combination drug to
improve medication adherence.
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OBJECTIVES: The goal of this study is to evaluate patient per-
sistence and adherence rates to HMG-CoA reductase inhibitors
(statins) in a managed care setting. METHODS: Retrospective
claims analysis of a nationwide managed care pharmacy data-
base was conducted for continuously beneﬁt-eligible patients
who were initiated on statin therapy from 1999 to 2002. Patients
were tracked for 12 months starting from the date of initial
